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Vandir dos Santos5, Bahjat F. Qaqish6, Evandro A. Rivitti3 and Luis A. Diaz1 for the
Cooperative Group on Fogo Selvagem Research
Fogo selvagem (FS), the endemic form of pemphigus foliaceus (PF), is an autoimmune blistering disease
characterized by autoantibodies against desmoglein 1. The Terena reservation of Limao Verde in Mato Grosso
do Sul, Brazil, is a previously identified focus of disease. Autoantibodies against desmoglein 3 (Dsg3) have also
been detected in sera from patients with FS. In an effort to further characterize the serological, geographical,
and clinical epidemiology of the disease, we sought to determine the prevalence of anti-Dsg3 autoantibodies in
sera from normal subjects living outside of and in an endemic area using an ELISA. Anti-Dsg3 antibodies
were detected in 53 of 146 normal subjects from Limao Verde (36%), and in eight of 140 normal subjects from
surrounding areas (6%). A significant trend was observed in the proportion of positive tests relative to distance
from the endemic area (Po0.001). Our seroepidemiological observations support the concept that the likely
environmental trigger of the antibody response in FS is located in this endemic area, and that the population
at risk to develop FS may also be at risk to develop an endemic form of pemphigus vulgaris as reported by our
co-investigators from Brasilia.
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INTRODUCTION
The Terena reservation of Limao Verde in Mato Grosso
do Sul, Brazil, is a well-known focus of fogo selvagem (FS),
the endemic form of pemphigus foliaceus (PF) (Hans-Filho
et al., 1996). This population of 1,200 individuals exhibits
a prevalence of FS of 3.4% with an incidence of one to
two new cases per year (Hans-Filho et al., 1996). We, along
with our Brazilian co-investigators, have closely followed
this human settlement by collecting periodic clinical,
serological, and epidemiological data since 1994. Anti-
desmoglein 1 (Dsg1) antibodies have been detected in sera
from the vast majority of patients with FS living in the
Limao Verde subregion using ELISA (Warren et al., 2000).
The prevalence of antibodies against Dsg1 is also high
among normal subjects living in this reservation (Warren
et al., 2000). Anti-Dsg1 autoantibodies from these normal
individuals, as well as from FS patients in clinical remission,
were shown to recognize epitopes located on the EC5
domain of the protein (Li et al., 2003). Additionally, by serial
serological evaluations of apparently normal individuals, the
presence of anti-Dsg1 antibodies was shown to precede
clinical disease by 1–7 years in a number of individuals who
go on to develop FS (Li et al., 2003; Warren et al., 2003). This
conversion to active clinical disease is associated with a shift
in the target of anti-Dsg1 autoantibodies toward epitopes in
the EC1 and EC2 ectodomains (Li et al., 2003). These
findings, along with the observation that the prevalence of
anti-Dsg1 antibodies increases gradually in populations with
closer proximity to the Limao Verde reservation (Warren
et al., 2000), have supported the notion that chronic
antigenic stimulation by an unknown environmental factor(s)
present in this human settlement may lead to anti-Dsg1
antibody production and subsequent clinical disease.
Antibodies against desmoglein 3 (Dsg3) have also been
detected in the sera of 19 of 276 (7%) previously studied
FS and PF patients by ELISA (Arteaga et al., 2002). Affinity-
purified antibodies to Dsg 3 from these patients induce a
pemphigus vulgaris (PV)-like skin disease in mice by passive
transfer, suggesting that a subset of patients with PF and FS
have antibodies to Dsg3 that may contribute in the
pathogenesis of the disease (Arteaga et al., 2002). Curiously,
anti-Dsg3 antibodies have also been detected in sera from
clinically normal individuals who reside in Limao Verde
(Li et al., 2003). This observation led us to extend our
serological screening of Limao Verde and neighboring
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Brazilian populations searching for sera containing
anti-Dsg3 autoantibodies. Characterization of the prevalence
of anti-Dsg3 antibodies in these populations may offer new
insight into the epidemiology of FS, and perhaps provide a
context for the existence of a novel form of ‘‘endemic PV’’
which has been observed in other Brazilian endemic areas of
FS (Rocha-Alvarez et al., 1995).
RESULTS
Antibodies against Dsg3 were detected by ELISA in nine of 21
patients with FS living in the endemic Limao Verde subregion
(43%). The prevalence of anti-Dsg3 antibodies among
normal subjects was 20% (61 of 304). A significant trend
was observed in the proportion of positive tests relative
to distance from the endemic area (Po0.001). Most of
the difference was between Limao Verde and the other
locations. However, a significant trend (P¼0.046) persists
among the six locations remaining after removing Limao
Verde from the analysis (Table 1, Figure 1). The ELISA for
anti-Dsg3 antibodies was negative in all 20 subjects (0%
positive) from Sao Paulo, a city located 1,200 km from Limao
Verde. Antibodies against Dsg3 were detected in one of 40
subjects from Campo Grande (3%, 160 km), and in one of 20
subjects from Aquidauana (5%, 25 km). Four of 40 subjects
from Corrego Seco (10%), which is part of the Limao Verde
reservation and located 6 km away from the subregion of
Limao Verde, tested positive for anti-Dsg3 antibodies. In
contrast, 53 of 146 normal subjects living in the Limao Verde
subregion (36%) possessed anti-Dsg3 antibodies. The Terena
reservation of Ipegue, which is 90 km west of the Limao
Verde subregion, is also a focus of endemic FS, however with
a much lower prevalence of disease (B0.1%) (Hans-Filho
et al., 1996). The ELISA for anti-Dsg3 antibodies was positive
in two of 20 normal subjects from this reservation (10%).
Tests for antibodies against Dsg3 were negative in all 18
normal subjects from the University of North Carolina at
Chapel Hill (UNC) blood bank and laboratory personnel.
Anti-Dsg1 antibodies were detected by ELISA in 20 of the
21 patients with FS (95%), as well as in 56 of 304 normal
subjects (18%). Of note, the one patient with FS who tested
negative was in clinical remission at the time of sample
collection. Testing of normal subjects for the presence of
anti-Dsg1 antibodies followed a similar pattern compared to
the detection of anti-Dsg3 antibodies in respect to geography.
The Dsg1 ELISA was positive in 44 of 146 normal subjects
living in the Limao Verde subregion (30%), in six of 40
subjects from Corrego Seco (15%), in five of 20 subjects from
Ipegue (25%), and in one of 40 subjects from Campo Grande
(3%). ELISA for anti-Dsg1 antibodies was negative in all 20
subjects from Aquidauana (0% positive), in all 20 subjects
from Sao Paulo (0% positive), and in all 18 subjects from
UNC (0% positive).
Table 1. Prevalence of anti-Dsg1 and anti-Dsg3 antibodies relative to distance from Limao Verde subregion1
Group/region
Distance from Limao Verde
subregion (km) Total (no.)
Positive anti-Dsg1 antibody
test (no. (%))
Positive anti-Dsg3 antibody
test (no. (%))
Patients with FS
Limao Verde 0 21 20 (95) 9 (43)
Normal subjects
Limao Verde 0 146 44 (30) 53 (36)
Corrego Seco 6 40 6 (15) 4 (10)
Aquidauana 25 20 0 (0) 1 (5)
Ipegue 90 20 5 (25) 2 (10)
Campo Grande 160 40 1 (3) 1 (3)
Sao Paulo 1,200 20 0 (0) 0 (0)
UNC-Chapel Hill 42,000 18 0 (0) 0 (0)
Dsg1, desmoglein 1; Dsg3, desmoglein 3; km, kilometer; FS, fogo selvagem; UNC, University of North Carolina.
1ELISA was performed using sera from patients with FS from Limao Verde, as well as from clinically normal subjects living in regions of varying proximity to
the endemic area. The proportion of positive tests in normal subjects decreases with distance from Limao Verde (Po0.001).
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Figure 1. Dsg3 ELISA index values, according to region. ELISA index values
from patients with FS and clinically normal subjects were grouped according
to region and plotted. The dashed horizontal line marks the cutoff value of 20
arbitrary units. Dsg3, desmoglein 3; ELISA, enzyme-linked immunosorbent
assay; FS, fogo selvagem; LV, Limao Verde; CS, Corrego Seco; UNC,
University of North Carolina at Chapel Hill.
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Antibodies against both Dsg1 and Dsg3 were detected by
ELISA in nine of 21 sera from patients with FS (43%), and in
46 of 304 normal subjects (15%). Solely anti-Dsg1 antibodies
were detected in 11 patients with FS (43%) and in 10 normal
subjects (3%). No sera from patients with FS tested positive
solely for the presence of anti-Dsg3 antibodies; whereas
solely anti-Dsg3 antibodies were detected in the sera of 15
of 304 normal subjects (5%). The proportion of sera from
clinically normal individuals that were positive for anti-Dsg3
antibodies was 82% among those also positive for anti-
Dsg1 antibodies, but only 6% among those who were
anti-Dsg1 antibody negative, suggesting a strong correlation
between anti-Dsg1 and anti-Dsg3 antibodies (Table 2). The
odds ratio estimate, stratified by region, was 65 (95% CI:
22–239). There was no significant heterogeneity in the odds
ratio between regions (P¼ 0.73).
Sera from 14 normal subjects from the Limao Verde
subregion tested strongly positive for the presence of
anti-Dsg3 autoantibodies by ELISA (index value 4100), and
were confirmed by immunoprecipitation (IP). Representa-
tive IP data are shown in Figure 2. The sera from normal
individuals exhibiting positive ELISA scores from 20 to 100
produced inconsistent results by IP. Indirect IF was negative
in all sera from normal subjects using normal human foreskin
as substrate. Autoantibodies against the intercellular spaces
were detected at titers ranging from 1:20 to 1:640 using
monkey esophagus as substrate in sera from all 13 normal
controls from the Limao Verde subregion in whom solely
anti-Dsg3 antibodies had been detected by ELISA.
All 21 patients from the Limao Verde subregion with
FS included in this study meet the established clinical
and histological criteria for diagnosis. Careful physical
examinations are periodically conducted by three dermato-
logists. No patients have shown any mucosal lesions
suggestive of PV to date.
DISCUSSION
The autoantibody response in humans directed toward the
desmosomal cadherins Dsg1 and Dsg3 is complex, diverse
(Payne et al., 2005), and ranges from a non-pathogenic and
persistent response detected in certain individuals lacking
clinical manifestations of disease to a frankly pathogenic one
found in PV, PF, and FS. It is well established that the sera of
the majority of PF and FS patients possess pathogenic anti-
Dsg1 IgG autoantibodies, predominantly of the IgG4 subclass
(Rock et al., 1989; Warren et al., 2003). Two variants of PV,
defined by clinical and serological means, have been
reported (Ding et al., 1997; Amagai et al., 1999b; Miyagawa
et al., 1999; Harman et al., 2001). The mucosal variant
exhibits a predominantly anti-Dsg3 antibody response, while
the mucocutaneous form, comprising approximately 50% of
patients with PV, is characterized by the presence of
both anti-Dsg3 and anti-Dsg1 autoantibodies. Importantly,
we have shown that both populations of autoantibodies in
this mucocutaneous form of PV are antigen specific and
induce the respective disease by passive transfer experiments
(Ding et al., 1999).
In the present investigation, we show a relatively high
prevalence of anti-Dsg3 antibodies by ELISA, similar to that of
anti-Dsg1 antibodies, in a Brazilian population where FS is
endemic. The respective prevalences of these autoantibodies
also mirror each other relative to geography (Table 1,
Figure 1). That is, the proportion of sera from normal subjects
that tested positive for anti-Dsg3 antibodies increased
with increasing proximity of their place of residence to the
endemic area. We show that the majority of sera exhibiting
high-index anti-Dsg3 ELISA values also immunoprecipitated
recombinant Dsg3 (Figure 2). These findings provide further
evidence that an environmental trigger may be involved in
the initial production of anti-Dsg1 and anti-Dsg3 antibodies
in individuals settled in these highly endemic regions of FS.
In susceptible individuals, these antibodies may lead to
clinical disease. Previously, we have suggested that the
emergence of pathogenic anti-Dsg1 autoantibodies in FS is
driven by epitope spreading of the antibody response from
the EC5 domain found in the pre-clinical stage of the disease
to the EC1–2 domain which is predominant in patients with
active disease (Li et al., 2003).
High degrees of sensitivity and specificity for the ELISA
assay using recombinant ectodomains of Dsg1 and Dsg3
have been reported in series of patients and controls from
different parts of the world (Amagai et al., 1999a,; Lenz et al.,
1999; Warren et al., 2000). The test has consequently
become a reliable means of identifying and classifying
patients with PF, FS, and PV. Indeed, the test detected anti-
Table 2. Anti-Dsg1 and anti-Dsg3 antibodies in
normal subjects are seroepidemiologically correlated1
Dsg3 ELISA
() (+) Total
Dsg1 ELISA
() 233 15 248
(+) 10 46 56
Total 243 61 304
Dsg1, desmoglein 1; Dsg3, desmoglein 3.
1Dsg1 and Dsg3 ELISA results from normal subjects were pooled and
placed in a 2 2 table for statistical analysis. The proportion of sera
positive for anti-Dsg3 antibodies was 82% among those also positive for
anti-Dsg1 antibodies, but only 6% among those who were anti-Dsg1
antibody negative, suggesting a correlation between the two antibodies
(odds ratio estimate, stratified by region, 65 (95% CI: 22–239)). There was
no significant heterogeneity in the odds ratio between regions (P=0.73).
373 >0336352<0<0<0NDND1000
1 2 3 4 5 6 7 8 9 10 11
Figure 2. Dsg3 IP and corresponding Dsg3 ELISA index value. (1) Negative
control from a normal human serum; (2) Positive control from PV serum;
(3 and 4) Normal human sera from the UNC blood bank; (5–11) Serum
samples from normal individuals living in Limao Verde, Mato Grosso, and
Brazil. ND, not determined.
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Dsg1 antibodies in 20 of 21 FS patients, and in all of those
with clinically active disease. Furthermore, the test was
negative in all clinically normal subjects from Sao Paulo and
UNC, areas far from endemic foci of disease. However, given
the increased number of positive tests for anti-Dsg1 and anti-
Dsg3 antibodies detected in sera of clinically normal
individuals from the Limao Verde reservation, the ELISA
technique used to detect these autoantibodies may have
limited utility as a diagnostic assay in endemic regions of FS.
This same observation has been described in other endemic
regions outside of Brazil, such as Tunisia (Kallel Sellami et al.,
2004). Future epitope-specific ELISA assays may be necessary
to distinguish pathogenic from non-pathogenic autoanti-
bodies as suggested by the studies of Li et al. (2003).
Given the shared homology between Dsg1 and Dsg3
(Goodwin et al., 1990; Buxton et al., 1993), it is possible that
the positive tests detecting antibodies to these respective
proteins in normal individuals could be the result of cross-
reactivity. Indeed, statistical analysis of the data obtained by
ELISA in this study suggests a strong correlation between the
two antibodies (odds ratio estimate, stratified by region 65
(95% CI: 22–239)). However, previously conducted immun-
absorption studies from sera from FS and PV patients
containing both anti-Dsg1 and anti-Dsg3 autoantibodies
suggest the presence of two populations of pathogenic
antibodies rather than one antibody capable of interacting
with both desmosomal cadherins (Arteaga et al., 2002; Ding
et al., 1997). Additionally, we found in the present study that
several normal subjects exhibited single antibody specificity
to either anti-Dsg1 or anti-Dsg3 antibodies in their sera. It is
likely that in a large population of individuals from an
endemic focus of FS, some may react only to Dsg1 or Dsg3,
while a great majority reacts to both antigens.
The disease phenotype associated with a determined
population of anti-Dsg1 and/or anti-Dsg3 antibodies in an
individual, as well as the evolution of these autoantibody
responses over time are subjects of interest in our laboratory.
Recent reports show that patients with classic clinical,
histological, and immunological findings of PV may evolve
into PF (Iwatsuki et al., 1991; Kawana et al., 1994; Chang
et al., 1997; Komai et al., 2001; Harman et al., 2002). The
evolution of PV into PF is associated with a serological switch
from antibodies against Dsg3, typical of PV, to antibodies
against Dsg1, which are a marker of PF. The transition from
PF into PV has also been described; however, this progression
appears to be extremely rare (Ishii et al., 2000). We have yet
to observe the transition from FS to PV in the Limao Verde
subregion; yet given the high prevalence of anti-Dsg3
antibodies in this population, we will continue to closely
follow these patients searching for clinical evidence that may
correlate with serological markers. It is unclear why patients
with FS whose sera contain anti-Dsg3 autoantibodies do
not exhibit a PV phenotype clinically. Curiously, previous
electron microscopic studies of oral mucosa of FS patients
have revealed acantholysis in this tissue despite the absence
of clinically visible lesions (Marcucci, 1978). It is conceivable
that the sera of these patients may contain insufficient
quantities of pathogenic anti-Dsg3 antibodies necessary to
induce skin or mucosal lesions characteristic of PV. This
theory appears to be re-enforced when testing the sera of FS
patients, which consistently immunoprecipitate recombinant
desmoglein 3 with less intensity than recombinant desmo-
glein 1 (rDsg1). Clearly, further studies are needed to define
the epitope specificity of these populations of anti-Dsg3
autoantibodies. However, given the overall prevalence of
anti-Dsg3 autoantibodies detected by ELISA in clinically
normal subjects in this study, as well as the observed
epidemiological trend in respect to geography, it can be
predicted that in endemic areas of FS, the population at risk to
develop FS may also be at risk to develop an endemic form of
PV as reported by our co-investigators from Brasilia (Rocha-
Alvarez et al., 1995).
In summary, this study shows that a significant number of
normal individuals living in the endemic focus of FS of Limao
Verde, Brazil possess anti-Dsg1 and anti-Dsg3 autoantibodies
in their sera. It is likely that in certain rare genetically
predisposed individuals, the anti-Dsg1 autoantibody response
leads to clinical FS. The great majority of these normal
individuals, however, remain disease free, perhaps for the
rest of their lives. Emergence of pathogenic anti-Dsg3
autoantibodies and clinical variants of PV in the endemic
regions of FS is likely to be an extremely uncommon
occurrence. Finally, the prevalence of anti-desmoglein
antibodies in respect to geography provides further evidence
that the likely environmental trigger of the anti-Dsg1 and anti-
Dsg3 autoantibody response is located among the population
of Limao Verde.
MATERIALS AND METHODS
Sources of sera
The sera available to carry out this study comprise the following: FS
patients (n: 21) from Limao Verde, as well as randomly selected
normal individuals from Limao Verde (n: 146) and Corrego Seco
(n: 40). We also included sera from normal individuals of the
Terena Reservation of Ipegue (n: 40) as well as samples from
the neighboring cities Aquidauana (n: 20), Campo Grande (n: 40),
and Sao Paulo (n: 20). A group of normal subjects from the UNC
Blood Bank and laboratory personnel was also tested (n: 18). Sera
were kept frozen at 201C at the Autoimmune Serum Bank of the
UNC Dermatology Research Laboratories until tested. This study
was approved by the Institutional Review Board at UNC. All clinical
investigation was conducted according to the Declaration of
Helsinki Principles. Participants gave their written informed consent.
Production and purification of rDsg1 and Dsg3
rDsg1 and rDsg3 containing the entire extracellular domain and a
C-terminal His-tag were generated in the baculovirus system and
purified by nickel affinity chromatography (Ding et al., 1997; Li
et al., 2003). Purified rDsg1 was used in the ELISA and IP protocols.
Dsg1 and Dsg3 ELISA assays
rDsg1 or rDsg3 was immobilized on immunomicrotiter plates (Costar,
Cambridge, MA) by overnight incubation at 41C. The plates were then
washed with Tris-buffered saline, pH 7.2 containing 3.7 mM calcium,
and 0.05% Tween 20 solution. After blocking with 1% BSA dissolved
in the previously described washing buffer, duplicate samples of a
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1:100 dilution of serum were incubated for 60 minutes. The plates
were washed and then incubated with a 1:1,000 dilution of
horseradish peroxidase-labelled mouse anti-human IgG (Zymed, San
Francisco, CA) for 60 minutes. ELISA values were expressed as an
index value, where OD stands for optical density as reported by
Amagai et al. (1999a).
Index value : ðtest sample ODÞðnegative control ODÞðpositive control ODÞðnegative control ODÞ100:
A cutoff value of 20 arbitrary units, previously determined by
analyzing a set of 57 human serum samples from normal donors of
the USA, was used to separate positive from negative sera. Values
below 20 were considered negative and above this number were
considered positive. A well-characterized FS serum sample was used
as a positive control.
Statistical analysis
The Cochran–Armitage test for trend in proportions was used in
Table 1. The conditional odds ratio and exact confidence interval
were used for 2 2 tables. Calculations were performed using
StatXact 4.0.1 (Cytel Software Corporation, San Francisco, CA).
Indirect immunofluorescence and IP
All patients and normal controls were tested by IIF using normal
human foreskin as substrate according to previous published
procedures (Matis et al., 1987). IIF using monkey esophagus was also
carried out using sera from normal controls from the Limao Verde
subregion in whom solely anti-Dsg3 antibodies had been detected by
ELISA. Cold IP coupled to immunoblotting, utilizing rDsg1 was also
performed according to previous related studies (Li et al., 2003).
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